The Medicus Pharma (MDCX) Playbook: De-Risking Drug Development for Double-Digit Returns
Artikel konnten nicht hinzugefügt werden
Der Titel konnte nicht zum Warenkorb hinzugefügt werden.
Der Titel konnte nicht zum Merkzettel hinzugefügt werden.
„Von Wunschzettel entfernen“ fehlgeschlagen.
„Podcast folgen“ fehlgeschlagen
„Podcast nicht mehr folgen“ fehlgeschlagen
The Medicus Pharma (MDCX) Playbook: De-Risking Drug Development for Double-Digit Returns
-
Gesprochen von:
-
Von:
Über diesen Titel
In this episode of the WTR Healthcare Happenings podcast, Tim Gerdeman, Vice Chair, Co‑Founder, and CMO of Water Tower Research, and Robert Sassoon, WTR’s Healthcare Research Analyst, speak with Dr. Raza Bokhari, Executive Chairman and CEO of Medicus Pharma (NASDAQ: MDCX). Dr. Bokhari outlines Medicus Pharma’s distinctive strategy of acquiring de‑risked, mid‑stage therapeutic assets and advancing them through Phase 2 development to attract major pharmaceutical partners. The discussion centers on the company’s two lead programs- Skinjet, a novel microneedle patch offering a non‑invasive alternative to surgery for non‑melanoma skin cancer, and Teverelix, a next‑generation therapy targeting prostate cancer and urinary retention. Dr. Bokhari elaborates on the company's strategic integration of generative AI through a partnership with Reliant AI to optimize clinical trial efficiency and outlines Medicus Pharma’s financial strategy, focusing on upcoming data readouts and non-dilutive capital through out-licensing opportunities.
